Abstract
Learning ObjectivesUpon completion of this activity, participants will be able to:Distinguish the most salient pathological feature of high myopia.Evaluate the long-term tolerability of atropine eye drops for myopia.Analyze the long-term efficacy of atropine eye drops for myopia.Assess variables that might alter the efficacy of atropine eye drops for myopia.Continuing Medical EducationIn support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at www.medscape.org/journal/eye; (4) view/print certificate.Credit hours1.0Release date:Expiration date: 21 September 2021Post-test link:https://medscape.org/eye/posttest934752Authors/Editors disclosure informationSobha Sivaprasad, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for: Allergan, Inc.; Apellis; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Novartis; Oculis; Optos; Oxurion; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. Jan Roelof Polling, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for: Théa Laboratories; Nevakar, Inc. Emily Tan, MD, has disclosed no relevant financial relationships. Sjoerd Driessen, MD, has disclosed no relevant financial relationships. Sjoukje E. Loudon, MD, has disclosed no relevant financial relationships. Hoi-Lam Wong, MD, has disclosed no relevant financial relationships. Astrid van der Schans, MD, PhD, has disclosed no relevant financial relationships. J. Willem Tideman, MD, has disclosed no relevant financial relationships. Caroline C. W. Klaver, MD, PhD, has disclosed the following relevant financial relationships: served as an advisor or consultant for: Bayer AG; Nevakar, Inc.; Novartis Pharmaceuticals Corporation; Théa Laboratories.Journal CME author disclosure informationCharles P. Vega, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for: GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Served as a speaker or a member of a speakers bureau for: Genentech, Inc.; GlaxoSmithKline.
Highlights
The prevalence of myopia is increasing all over the world, and has reached the highest frequencies in young adults in South Korea (96.5%), but has increased significantly in Europe (49.2%) [1, 2]
In children with or at risk of developing high myopia, a starting dose of atropine 0.5% was associated with decreased progression in European children during a 3-year treatment regimen
Myopia carries a significant risk of retinal detachment, glaucoma, and myopic macular degeneration, which is most prominent for severe refractive errors [6]
Summary
The prevalence of myopia is increasing all over the world, and has reached the highest frequencies in young adults in South Korea (96.5%), but has increased significantly in Europe (49.2%) [1, 2]. I.e. refractive errors −6D or more, has increased from 4.2 to 21.6% in EastAsians and from 1.4 to 5.3% in Europeans [2, 4]. Myopia carries a significant risk of retinal detachment, glaucoma, and myopic macular degeneration, which is most prominent for severe refractive errors [6]. Of those with high myopia, one in three develops bilateral severe visual impairment or blindness with age [7]. Atropine is the most powerful treatment for progressive myopia in childhood. This study explores the 3-year effectiveness of atropine in a clinical setting
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
